Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
Abstract
The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our center.
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
Abstract
Chronic hepatitis B (CHB) infection is the major cause of hepatocellular carcinoma (HCC). Primary prevention of hepatitis B infection by vaccination is effective in reducing the incidence of HCC. In persons with CHB infection, the two accepted treatment modalities are
Direct-acting antiviral agents and the path to interferon independence
Abstract
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximatel y 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies.
Hard-to-treat patient with hepatitis C – what will change with interferon-free therapy?
Abstract
The article explores current and future approaches to the management of hard-to-treat patients with chronic HCV infection. Specific features of hard-totreat patients are reviewed in the context of upcoming implementation of IFN-free regimens. Recently published data resulted
Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Abstract
The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and ribavirin (RBV). Although it is effective in a high percentage of patients, this treatment is associated with
Protease inhibitors for prophylaxis mother-to-child HIV transmission
Abstract
A substantial part of HIV-infected women are of child-bearing age. This enhances the need for prophylaxis of mother-to-child transmission. According to modern guidelines the most the three-stage approach (during pregnancy, during labor and to the newborn) is most effective.
Detection of LAM-antigen in urine as a rapid method of diacnostics of tuberculosis in HIV-infected patients
Abstract
LAM-ELISA is a new method of laboratory diagnostics of tuberculosis in HIV-positive patients based on detection of the cell wall lipoarabinomannan of Mycobacterium sp. in urine. The test sensitivity increases with decreasing number of CD4 + -lymphocytes and peaks at 50
Elastometry in complex assessment of hepatic fibrosis in patients with HIV and HIV/VHC coinfected patients
Abstract
314 HIV-infected patients were examined in this trial including 281 patients with HIV/HCV co-infection an d 33 patients with HIV mono-infection. Anti-HCV therapy and HAART (Highly Active Antiretroviral Therapy) wasn`t prescribed to the all patients earlier. Fibrosis was
Pharmacoeconomic aspects of HIV therapy with the use of highly active anti-retroviral therapy fixed dose combination (emtricitabine/rilpivirine/ tenofovir)
Abstract
Fixed-doze combination of rilpivirine, tenofovir andemtricitabine in highly active antiretroviral therapy makes possible to decrease costs comparing to combinations of rilpivirine with fixed doze tenofovir/emtricitabine and raltegravir with fixed doze tenofovir/emtricitabine